Analysis of the risk of sudden discontinuation of tazetostat (Daveco) after taking it for 6 months

Tazemetostat (Tazemetostat) is a selective EZH2 inhibitor commonly used to treat relapsed or refractory follicular lymphoma and other tumors with EZH2 gene mutations. The drug blocks the growth and spread of tumor cells by inhibiting abnormal epigenetic regulation. Since its mechanism of action requires continuous inhibition of EZH2 activity, patients often need long-term regular medication to maintain the efficacy.

If the drug is suddenly stopped after taking it for 6 months, the first risk is that the tumor may progress rapidly. Although some patients achieve remission during treatment, the cancer cells have not been completely eliminated. Stopping the drug will quickly disappear the effect of the drug that inhibits EZH2, leading to the repopulation of the remaining malignant cells. Clinically, it has been reported that some patients have significant recurrence or worsening of the disease within a short period of time after stopping the drug.

Secondly, sudden discontinuation may also increase the risk of drug resistance or reduced efficacy. If a patient subsequently attempts to use tazerestat again, drug sensitivity may decrease, making retreatment less effective than initial treatment. Especially for patients who are in a relapsed or refractory state, once the best control opportunity is missed, the options for re-treatment will be even smaller.

Therefore, for patients taking tazerestat, if discontinuation of the drug is considered, it should be done under strict evaluation and monitoring by a physician rather than interrupting treatment on your own. Doctors may adjust the treatment plan based on disease progression, adverse drug reactions, or efficacy evaluation, and use alternative drugs or combination treatment strategies when necessary. In short, the risk of sudden drug discontinuation is high, and patients should maintain good follow-up and medication compliance to maximize benefits and reduce the possibility of recurrence.

Reference materials:https://www.drugs.com/